Éric Legouffe
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- HER2/EGFR in Cancer Research
Papers in
- Hematology 15
- Multiple Myeloma Research and Treatments 12
- Oncology 14
- HER2/EGFR in Cancer Research 4
- Co-authors
- Bernard Klein (17 shared papers)Karin Tarte (9 shared papers)Éric Jourdan (5 shared papers)Jérôme Moreaux (5 shared papers)Thierry Rème (5 shared papers)Jean‐François Rossi (10 shared papers)Jean François Rossi (7 shared papers)John De Vos (5 shared papers)
- Journals
- Blood (11 papers)Annals of Oncology (6 papers)Bone Marrow Transplantation (3 papers)Journal of Clinical Oncology (3 papers)The Lancet Oncology (3 papers)
- Partner nations
- FranceLuxembourgUnited States
In The Last Decade
Éric Legouffe
49 papers receiving 3.8k citations
Éric Legouffe's Hit Papers
Peers
Comparison fields: 5 of 95
- Hematology 1.1k
- Oncology 1.3k
- Genetics 486
- Cancer Research 618
- Immunology 695
Countries citing papers authored by Éric Legouffe
This map shows the geographic impact of Éric Legouffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Legouffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Legouffe more than expected).
Fields of papers citing papers by Éric Legouffe
This network shows the impact of papers produced by Éric Legouffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Legouffe. The network helps show where Éric Legouffe may publish in the future.
Co-authors
The 25 scholars most cited alongside Éric Legouffe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study Hit paper breakdown → | 2012 | 591 |
| 2 | 2003 | 467 | |
| 3 | Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2022 | 248 |
| 4 | 2005 | 217 | |
| 5 | 2002 | 213 | |
| 6 | 2006 | 203 | |
| 7 | 2011 | 197 | |
| 8 | 2015 | 184 | |
| 9 | 2003 | 183 | |
| 10 | 2012 | 138 | |
| 11 | 2015 | 133 | |
| 12 | 2002 | 120 | |
| 13 | 1998 | 114 | |
| 14 | 1998 | 107 | |
| 15 | 2019 | 104 | |
| 16 | Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. | 1999 | 89 |
| 17 | 2014 | 73 | |
| 18 | 2004 | 59 | |
| 19 | 1998 | 54 | |
| 20 | 2005 | 47 |
About Éric Legouffe
Éric Legouffe is a scholar working on Hematology, Oncology, Pathology and Forensic Medicine, Genetics and Immunology, having authored 51 papers that have together received 4.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (12 papers), Lymphoma Diagnosis and Treatment (8 papers), Immunotherapy and Immune Responses (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Renal cell carcinoma treatment (4 papers), HER2/EGFR in Cancer Research (4 papers), T-cell and B-cell Immunology (4 papers) and Advanced Breast Cancer Therapies (4 papers). The work is most often cited by research in Hematology (1.1k citations), Oncology (1.3k citations), Genetics (486 citations), Cancer Research (618 citations) and Immunology (695 citations). Éric Legouffe has collaborated with scholars based in France, Luxembourg and United States. Frequent co-authors include Bernard Klein, Karin Tarte, Éric Jourdan, Jérôme Moreaux, Thierry Rème, Jean‐François Rossi, Jean François Rossi, John De Vos, Philippe Quittet and Sophie Abadie‐Lacourtoisie. Their work appears in journals such as Blood, Annals of Oncology, Bone Marrow Transplantation, Journal of Clinical Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.